Terug
35
63
Dagbereik
€ 0,30
€ 0,34
52-Weeksbereik
€ 0,18
€ 0,43
Volume
100
50D / 200D Gem.
€ 0,31
/
€ 0,27
Vorige Slotkoers
€ 0,34
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 4,3 | 0,4 |
| P/B | 0,2 | 2,9 |
| ROE % | 4,5 | 3,7 |
| Net Margin % | 8,4 | 3,9 |
| Rev Growth 5Y % | 29,9 | 10,0 |
| D/E | 0,3 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2029 |
€ 0,00
€ 0,00 – € 0,00
|
840 M | 0 |
| FY2028 |
€ 0,00
€ 0,00 – € 0,00
|
1 B | 0 |
| FY2027 |
€ 0,16
€ 0,16 – € 0,16
|
2,7 B | 1 |
Belangrijkste Punten
Revenue grew 29,94% annually over 5 years — strong growth
ROE of 4,47% is below average
Debt/Equity of 0,34 — conservative balance sheet
Generating 182,32M in free cash flow
P/E of 4,33 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 37,78%
Groei
Revenue Growth (5Y)
29,94%
Revenue (1Y)-7,84%
Earnings (1Y)N/A
FCF Growth (3Y)15,48%
Kwaliteit
Return on Equity
4,47%
ROIC3,98%
Net Margin8,42%
Op. Margin13,57%
Veiligheid
Debt / Equity
0,34
Current Ratio1,67
Interest Coverage5,00
Waardering
P/E Ratio
4,33
P/B Ratio0,19
EV/EBITDA3,96
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -7,84% | Revenue Growth (3Y) | -8,63% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 29,94% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 1,99B | Net Income (TTM) | 167,29M |
| ROE | 4,47% | ROA | 2,37% |
| Gross Margin | 34,60% | Operating Margin | 13,57% |
| Net Margin | 8,42% | Free Cash Flow (TTM) | 182,32M |
| ROIC | 3,98% | FCF Growth (3Y) | 15,48% |
| Safety | |||
| Debt / Equity | 0,34 | Current Ratio | 1,67 |
| Interest Coverage | 5,00 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 4,33 | P/B Ratio | 0,19 |
| P/S Ratio | 0,36 | PEG Ratio | -0,03 |
| EV/EBITDA | 3,96 | Dividend Yield | 0,00% |
| Market Cap | 724,45M | Enterprise Value | 1,07B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 1,99B | 2,16B | 2,38B | 2,10B | 696,96M |
| Net Income | 167,29M | -116,11M | -528,48M | 287,55M | -386,88M |
| EPS (Diluted) | 0,06 | -0,06 | -0,28 | 0,15 | -0,25 |
| Gross Profit | 687,40M | 738,43M | 815,68M | 650,98M | 304,87M |
| Operating Income | 269,59M | 192,68M | 269,35M | 236,90M | 115,57M |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 7,05B | 7,45B | 7,92B | 8,04B | 8,15B |
| Total Liabilities | 3,23B | 3,76B | 4,32B | 4,13B | 4,40B |
| Shareholders' Equity | 3,80B | 3,69B | 3,60B | 3,91B | 3,76B |
| Total Debt | 1,28B | 1,90B | 2,82B | 2,65B | 2,97B |
| Cash & Equivalents | 941,58M | 1,04B | 678,57M | 800,95M | 2,31B |
| Current Assets | 1,88B | 2,03B | 1,94B | 1,98B | 3,35B |
| Current Liabilities | 1,13B | 1,53B | 2,67B | 926,60M | 735,67M |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#545 of 820
#59 of 708
Recente Activiteit
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026